Zalevsky Jonathan's Insider Trades & SAST Disclosures
Zalevsky Jonathan's most recent trade in Nektar Therapeutics was a trade of 10,300 Common Stock done at an average price of $1.0 . Disclosure was reported to the exchange on Feb. 19, 2025.
Add Superstar Alert
Note
This is a custom search result for pattern Zalevsky Jonathan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 19 Feb 2025 | 10,300 | 316,604 (0%) | 0% | 1.0 | 10,403 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 0.94 per share. | 19 Dec 2024 | 51,115 | 326,904 (0%) | 0% | 0.9 | 48,048 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 375,000 | 375,000 | - | - | Stock Option | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 270,000 | 270,000 | - | - | Stock Option | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 135,000 | 378,019 (0%) | 0% | 0 | Common Stock | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 19 Nov 2024 | 7,785 | 243,019 (0%) | 0% | 1.0 | 7,863 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 1.28 per share. | 19 Aug 2024 | 6,866 | 250,804 (0%) | 0% | 1.3 | 8,788 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 1.75 per share. | 17 May 2024 | 7,355 | 257,670 (0%) | 0% | 1.7 | 12,871 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Zalevsky Jonathan | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 0.68 per share. | 20 Feb 2024 | 9,014 | 265,025 (0%) | 0% | 0.7 | 6,130 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 250,000 | 250,000 | - | - | Stock Option | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 16 Aug 2023 | 9,703 | 283,685 (0%) | 0% | 0.8 | 7,568 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 0.72 per share. | 16 May 2023 | 9,791 | 293,388 (0%) | 0% | 0.7 | 7,050 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 16 Feb 2023 | 10,484 | 303,179 (0%) | 0% | 3 | 31,452 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 4.65 per share. | 18 Aug 2022 | 73,716 | 327,123 (0%) | 0% | 4.6 | 342,779 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 270,000 | 270,000 | - | - | Common Stock | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 135,000 | 411,399 (0%) | 0% | 0 | Common Stock | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 4.76 per share. | 15 Aug 2022 | 10,560 | 400,839 (0%) | 0% | 4.8 | 50,266 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2022 | 23,950 | 298,072 (0%) | 0% | 0 | Common Stock | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 3.95 per share. | 15 May 2022 | 21,673 | 276,399 (0%) | 0% | 3.9 | 85,608 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 10.95 per share. | 16 Feb 2022 | 10,912 | 274,122 (0%) | 0% | 10.9 | 119,486 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 94,000 | 94,000 | - | - | Stock Option | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 52,950 | 285,034 (0%) | 0% | 0 | Common Stock | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 40,150 | 252,953 (0%) | 0% | 0 | Common Stock | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 13.16 per share. | 15 Nov 2021 | 20,869 | 232,084 (0%) | 0% | 13.2 | 274,636 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2021 | 71,550 | 71,550 | - | - | Stock Option | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 13.83 per share. | 16 Aug 2021 | 7,662 | 212,803 (0%) | 0% | 13.8 | 105,965 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 17 May 2021 | 31,111 | 235,065 (0%) | 0% | 18.3 | 569,331 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 22.37 per share. | 16 Feb 2021 | 24,141 | 266,176 (0%) | 0% | 22.4 | 540,034 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 71,500 | 71,500 | - | - | Stock Option | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 40,000 | 290,317 (0%) | 0% | 0 | Common Stock | |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 16.40 per share. | 23 Nov 2020 | 16,380 | 250,317 (0%) | 0% | 16.4 | 268,632 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 16.93 per share. | 16 Nov 2020 | 29,618 | 266,697 (0%) | 0% | 16.9 | 501,433 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 19.67 per share. | 17 Aug 2020 | 26,200 | 296,315 (0%) | 0% | 19.7 | 515,354 | Common Stock |
|
Nektar Therapeutics
Board Meeting |
Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 22.51 per share. | 18 May 2020 | 4,558 | 322,515 (0%) | 0% | 22.5 | 102,601 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges